No link to cardiac valvulopathy was seen in cabergoline treated patients

No link to cardiac valvulopathy was seen in cabergoline treated patients

<p><strong>Objective:</strong> To evaluate the association between use of cabergoline in patients with prolactinoma and risk of developing clinically relevant cardiac valvular disease.</p> <p><strong>Method:</strong> This was a descriptive cross sectional st...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	K Dharshini, Noel Somasundaram, HMDPK Senevirathna, S Raj Kumar
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Sri Lanka College of Endocrinologists 2012-10-01
Sraith:	Sri Lanka Journal of Diabetes Endocrinology and Metabolism
Ábhair:	prolactinoma cabergoline valvulopathy
Rochtain ar líne:	https://sjdem.sljol.info/articles/4775

Míreanna comhchosúla

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
de réir: Shruti Khare, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
de réir: Annabelle G Hayes, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
de réir: Youngki Lee, et al.
Foilsithe / Cruthaithe: (2014-09-01)

Spontaneous reduction of prolactinoma post cabergoline withdrawal
de réir: Sampath Kumar Venkatesh, et al.
Foilsithe / Cruthaithe: (2012-01-01)

The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
de réir: Larisa Dzeranova, et al.
Foilsithe / Cruthaithe: (2016-11-01)

Cabergoline-induced tricuspid regurgitation: Case report and review of literature
de réir: Mohammad Hayat Bhat, et al.
Foilsithe / Cruthaithe: (2011-01-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
de réir: Bassam M Flamerz Arkawazi
Foilsithe / Cruthaithe: (2020-01-01)

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors
de réir: Galina Afanas'evna Melnichenko, et al.
Foilsithe / Cruthaithe: (2015-04-01)

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report
de réir: Luiz Augusto Casulari, et al.
Foilsithe / Cruthaithe: (2019-06-01)

Management of prolactinoma with cabergoline treatment in a pregnant woman during her entire pregnancy
de réir: Sukhwinder Kaur Bajwa, et al.
Foilsithe / Cruthaithe: (2011-01-01)

Subarachnoid Hemorrhage Due to Rupture of an Intracavernous Carotid Artery Aneurysm Coexisting with a Prolactinoma under Cabergoline Treatment
de réir: Nobuyuki Akutsu, et al.
Foilsithe / Cruthaithe: (2014-03-01)

Second attempt of Cabergoline withdrawal in patients with prolactinomas after a failed first attempt : is it worthwhile?
de réir: Lucio eVilar, et al.
Foilsithe / Cruthaithe: (2015-02-01)

The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
de réir: Zilya A. Kalmykova, et al.
Foilsithe / Cruthaithe: (2019-09-01)

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
de réir: Ana Carolina Correa e Castro, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Histopathologic characterization of lesios in rheumatic valvulopathy
de réir: R. Ricca, et al.
Foilsithe / Cruthaithe: (2010-01-01)

VISUAL FIELD DEFECTS SECONDARY TO CABERGOLINE USE IN A PATIENT WITH PITUITARY TUMOR
de réir: sylvia andrea araneda, et al.
Foilsithe / Cruthaithe: (2015-02-01)

Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience
de réir: Tuğba Kontbay, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
de réir: Edward Mignone, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Makroprolaktinoma da Kabergolin Tedavisinin Etkinliği
de réir: Derya Buluş
Foilsithe / Cruthaithe: (2017-09-01)

Temozolomide in treatment resistant prolactinomas
de réir: V. N. Shree, et al.
Foilsithe / Cruthaithe: (2018-08-01)

Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin
de réir: Ludmila I. Astafyeva, et al.
Foilsithe / Cruthaithe: (2018-03-01)

Pathogenesis, diagnosis and current treatment of prolactinoma: a review of the literature
de réir: Monika Szyszka, et al.
Foilsithe / Cruthaithe: (2024-07-01)

A clinical case of effective treatment of giant prolactinoma in patient with morbid obesity
Foilsithe / Cruthaithe: (2014-06-01)

Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
de réir: Cristina Laguna Benetti-Pinto, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
de réir: Irena A. Ilovayskaya, et al.
Foilsithe / Cruthaithe: (2023-12-01)

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
de réir: Michele Basile, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Prolactinomas: evolution after menopause
de réir: Maria Susana Mallea-Gil, et al.

Lymphangioleiomyomatosis associated with prolactinoma: A case report and literature review
de réir: Yosuke Murakami, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
de réir: Motofumi Koguchi, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Cardiovascular Imaging in Pregnancy: Valvulopathy, Hypertrophic Cardiomyopathy, and Aortopathy
de réir: Haneen Ismail, et al.
Foilsithe / Cruthaithe: (2022-08-01)

CABERGOLINE IN PRACTICAL MAMMOLOGY
de réir: I. V. Vysotskaya, et al.
Foilsithe / Cruthaithe: (2016-12-01)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
de réir: Sunita M C De Sousa
Foilsithe / Cruthaithe: (2023-01-01)

Klinicheskiy sluchay gigantskoy prolaktin-sekretiruyushchey adenomy gipofiza u podrostka
Foilsithe / Cruthaithe: (2010-06-01)

The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene
de réir: Laurent Vroonen, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
de réir: Claudia Pivonello, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Cabergoline-induced mania in a patient of pituitary microadenoma
de réir: Satyakam Mohapatra, et al.
Foilsithe / Cruthaithe: (2017-01-01)

The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma
de réir: Mehnaz Mustary Shume, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Macroprolactinoma resistente aos agonistas dopaminérgicos: relato de caso Macroprolactinoma resistant to dopamine agonists: a case report
de réir: Rosana Maria dos Reis, et al.
Foilsithe / Cruthaithe: (2004-09-01)

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
de réir: Muhammed Kizilgul, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Prolactinoma - which patients react favorably to cabergoline medication?
de réir: Karatas Savas, et al.
Foilsithe / Cruthaithe: (2022-10-01)